Heparin-induced thrombocytopenia: 2008 Update

Current Treatment Options in Cardiovascular Medicine

Volumn 10, Issue 2, 2008, Pages 117-127

  Bartholomew, John R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; ARGATROBAN; COUMARIN; DANAPAROID; FONDAPARINUX; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; WARFARIN;

AMPUTATION; APLASTIC ANEMIA; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ERYTHEMA; GANGRENE; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERSPLENISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOASSAY; INJECTION SITE NECROSIS; INTRACARDIAC THROMBOSIS; LABORATORY TEST; LOW DRUG DOSE; LUNG EMBOLISM; PATHOGENESIS; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SIDE EFFECT; SKIN NECROSIS; SKIN NODULE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

EID: 41749088267     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-008-0013-1     Document Type: Review

References (51)

1. Warkentin TE: Heparin induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003, 123:373-374.
2. Warkentin TE, Levine MN, Hirsh J, et al.: Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
3. Prandoni P, Siragusa S, Girolami B, Fabris F: The incidence of heparin-induced thrombocytopenia in medical patients treated with low molecular weight heparin: a prospective cohort study. Blood 2005, 106:3049-3054.
4. Oliveira GB, Anstrom KJ, Honeycutt EF, et al.: Days on intravenous heparin predict thrombocytopenia and drop in platelet count on heparin predicts mortality; findings from the Complications After Thrombocytopenia Caused by Heparin (CATCH) registry [abstract]. Circulation 2004, 110(Suppl):2604.
5. Warkentin TE, Greinacher A: Heparin induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(Suppl 4):311S-337S.
6. Mattel N, Lee J, Wells PS: Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005, 106:2710-2715.
7. Cines DB, Rauova L, Arepally G, et al.: Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher 2007, 22:31-36.
8. Warkentin TE, Sheppard JAI: Testing from heparin-induced thrombocytopenia antibodies. Transfus Med Rev 2006, 20:254-272.
9. Kelton JG: The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest 2005, 127:9S-20S.
10. Bartholomew JR, Begelman SM, AlMahameed A: Heparin-induced thrombocytopenia: principles for early recognition and management. Cleve Clin J Med 2005, 72(Suppl 1):S31-36.
11. Warkentin TE: Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998, 35(Suppl):9-16.
12. Warkentin TE, Roberts RS, Hirsh J, et al.: An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003, 163:2518-2524.
13. Arepally GM, Ortel TL: Heparin-induced thrombocytopenia. N Engl J Med 2006, 355:809-817.
14. Warkentin TE, Kelton JG: A 14 year study of heparin-induced thrombocytopenia. Am J Med 1996, 101:502-507.
15. Liu JC, Lewis BE, Steen LH, et al.: Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. Am J Cardiol 2002, 89:979-981.
16. Warkentin TE, Elavathil LJ, Hayward CPM, et al.: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997, 127:804-812.
17. Srinivasan AF, Rice L, Bartholomew JR, et al.: Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004, 164:66-70.
18. Warkentin TE: Coumarin-induced skin necrosis and venous limb gangrene. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice, edn 5. Edited by Colman RW, Marder VJ, Clowes AW, et al.: Philadelphia: Lippincott Williams & Wilkins; 2006:1663-1671.
19. Warkentin TE: Clinical picture of heparin-induced thrombocytopenia. In Heparin-Induced Thrombocytopenia, edn 4. Edited by Warkentin TE, Greinacher A. New York: Marcel Dekker; 2007:21-66, 90.
20. Mims MP, Manian P, Rice L: Acute cardiorespiratory collapse from heparin: a consequence of heparin-induced thrombocytopenia. Eur J Haematol 2004, 72:366-369.
21. Warkentin TE, Kelton JG: Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001, 344:1286-1292.
22. Warkentin TE, Heddle NM: Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003, 2:148-157.
23. Warkentin TE, Sheppard JA, Moore JC, et al.: Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005, 146:341-346.
24. Zwicker JI, Uhl L, Huang WY, et al.: Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004, 2:2133-2137.
25. Greinacher A, Eichler P, Lubenow N, et al.: Heparin-induced thrombocytopenia with thromboembolic complications; meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000, 96:846-851.
26. Lubenow N, Eichler P, Lietz T, Greinacher A, HIT Investigators Group: Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2 and HAT-3. J Thromb Haemost 2005, 3:2428-2436.
27. Lewis BE, Wallis DE, Berkowitz SD, et al.: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103:1838-1843.
28. Hirsh J, Heddle N, Kelton JG: Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004, 164:361-369.
29. Song X, Huhte G, Wang L, et al.: Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999, 100:1528-1532.
30. Greinacher A, Lubenow N, Eichler P: Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003, 108:2062-2065.
31. Lewis BE, Wallis DE, Leya F, et al.: Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003, 163:1849-1856.
32. Baghdasarian S, Singh I, Militello MA, et al.: Argatroban dosage in critically ill patients with HIT [abstract]. Blood 2004, 104:1179.
33. Mahaffey KW, Lewis BE, Wilderman NM, et al.: ATBAT Investigators: The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 2003, 15:611-616.
34. Chamberlin JR, Lewis B, Leya F, et al.: Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol 1995, 11:511-514.
35. Ramirez L, Carman T, Begelman SM, Bartholomew JR: Bivalirudin in patients with HIT or clinically suspected HIT [abstract 918]. Blood 2005, 106:269a.
36. Bartholomew JR: Bivalirudin for the treatment of heparin-induced thrombocytopenia. In Heparin-Induced Thrombocytopenia, edn 4. Edited by Warkentin TE, Greinacher A. New York: Marcel Dekker; 2007.
37. Dyke CM, Aldea G, Koster A, et al.: Off pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or anti-platelet factor 4/heparin antibodies. Ann Thorac Surg 2007, 84:836-839.
38. Koster A, Dyke CM, Aldea G, et al.: Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg. 2007 83:572-577.
39. Efird LE, Kockler DR: Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 2006, 40:1383-1387.
40. Warkentin TE, Cook RJ, Marder VJ, et al.: Anti-platelet factor 4/ heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005, 106:3791-3796.
41. Warkentin TE, Maurer BT, Aster RH: Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007, 356:2653-2655.
42. Warkentin TE, Greinacher A, Craven S, et al.: Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explaining their variable prothrombin time prolongation. Thromb Haemost 2005, 94:958-964.
43. Sheth SB, DiCicco RA, Hursting MJ, et al.: Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001, 85:435-440.
44. Kearon C, Johnston M, Moffat K, et al.: Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med 1998, 158:1140-1143.
45. Keeling D, Davidson S, Watson H, on behalf of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology: The management of heparin-induced thrombocytopenia. Br J Haematol 2006, 133:259-269.
46. Potzsch B, Klovekorn WP, Madlener K: Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia [letter]. N Engl J Med 2000, 343:515.
47. Wallis DE, Workman KL, Lewis BE, et al.: Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999, 106:629-635.
48. Lewis BE, Matthai WH, Cohen M, et al.: Argatroban anti-coagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002, 57:177-184.
49. Mattioli AV, Bonetti L, Sternieri S, Mattioli G: Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J 2000, 1:39-42.
50. Williams RT, Damaraju LV, Mascelli MA, et al.: Anti-platelet factor 4/ heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 2003, 107:2307-2312.
51. Caiola E: Heparin-induced thrombocytopenia: how to manage it, how to avoid it. Cleve Clin J Med 2000, 67:621-624.